Over 200 Total Lots Up For Auction at One Location - UT 06/15

Siteman Cancer Center at Washington University treats 2,000th patient with MRIdian MR-guided radiotherapy

Press releases may be edited for formatting or style | March 02, 2023 MRI Rad Oncology
DENVER, March 2, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the clinical team at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis has treated its 2,000th patient using the MRIdian, MRI-guided radiation therapy system. Patients treated at Siteman Cancer Center benefit from MRIdian's diagnostic quality MR visualization on-table adaptive radiotherapy, real-time tissue tracking, and automated beam control. In January 2014, Siteman Cancer Center became the first to treat patients using the world's first MRI-guided radiation therapy system – MRIdian by ViewRay. The clinical team at Washington University has been a leader in publishing clinical evidence related to treating various cancers, including pancreas, prostate, lung, liver, breast, and oligometastatic cancers.

The Siteman Cancer Center team has generated foundational peer-reviewed clinical evidence for MRIdian MRI-guided radiation therapy SBRT (stereotactic body radiotherapy). The body of clinical evidence includes early studies demonstrating that pancreatic cancer patients treated with ablative doses contribute to extended survival; feasibility of on-table adaptive MRIdian SMART (stereotactic MRI-guided adaptive radiotherapy) for unresectable primary or oligometastatic malignancies in the abdomen and central thorax. The team led the way in publishing clinical studies demonstrating the use of MRI-guided SBRT to treat liver tumors and has one of the largest volumes of patients. This clinical team was the first to publish prospective clinical trial data in pancreatic cancer patients and has treated the largest volume of breast cancer patients with MRIdian SMART, highlighting the effective use of short-course (single fraction) treatment.

"As we commemorate our tenth year treating with MRIdian, we continue to see the data indicating the benefits of MRI-guided radiation therapy for our patients. MR guidance and adaptive radiation therapy enable highly therapeutic cancer treatments while minimizing side effects, improving quality of life, and potentially even improving survival," said Hyun Kim, M.D., Associate Professor of Radiation Oncology and MR Clinical Service Chief at Siteman Cancer Center and Washington University School of Medicine. "MRIdian has demonstrated in actual patient treatment data the importance of MRI guidance with adaptive therapy to address anatomical and tumor changes, real-time soft tissue tracking, and automated beam control. We treat more than 270 patients per year and are pleased that we were able to offer this advanced treatment modality to more than 2,000 patients over the years."
DOTmed text ad

New Fully Configured 80-slice CT in 2 weeks with Software Upgrades for Life

For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.


You Must Be Logged In To Post A Comment